Answers are grounded in this paper and cite their sources.
This analysis questions the use of time to symptom elimination as a primary endpoint in respiratory virus trials, suggesting a more efficient alternative.
Time to symptom elimination is a statistically inefficient endpoint for respiratory virus trials that ignores the most clinically relevant timepoints. Alternatively, clearance slope and area under the curve may efficiently capture improvement early during treatment when symptoms are most severe.
No takes yet. Share an insight, caveat, or question.
Schiffer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: